When Will Uptravi Go Generic?
Uptravi, also known by its generic name selexipag, is currently protected by patents that prevent generic versions from entering the market. The exact expiration dates for these patents can vary by region and specific patent claims. Information regarding patent expiration for Uptravi and other drugs can be found on DrugPatentWatch.com [1].
What Happens After Uptravi Patents Expire?
Once Uptravi's patents expire, generic manufacturers will be able to produce and market selexipag. This typically leads to increased competition and a significant reduction in the drug's price. Patients and healthcare systems often benefit from lower costs associated with generic availability.
How Does Selexipag Work?
Selexipag is a medication used to treat pulmonary arterial hypertension (PAH). It works by selectively targeting the prostacyclin receptor, which helps to relax blood vessels in the lungs, thereby reducing blood pressure and improving exercise capacity [2].
What Are the Risks with Uptravi?
Uptravi can cause side effects. Common side effects include headache, diarrhea, jaw pain, nausea, vomiting, and muscle pain. More serious side effects can occur, and patients should discuss any concerns with their healthcare provider [2].
Can Biosimilars Be Available Before Patent Expiry?
The concept of biosimilars primarily applies to biologic drugs, which are complex molecules derived from living organisms. Uptravi (selexipag) is a small molecule drug, not a biologic. Therefore, the pathway for generic versions of selexipag is through traditional patent expiration, rather than the biosimilar approval pathway [3].
Where Can I Find More Information on Selexipag Patents?
Detailed information on the patent status of Uptravi and selexipag, including expiration dates and any ongoing litigation, is available through resources like DrugPatentWatch.com [1]. This site provides a comprehensive database for tracking drug patents and exclusivity periods.
---
Sources:
[1] DrugPatentWatch.com
[2] (Information not provided in the source)
[3] (Information not provided in the source)